Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2014 Financial Results on November 13, 2014
SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2014 financial results will be released after close of market on Thursday, November 13, 2014 .  Following the announcement, Veracyte's management will host a live
View HTML
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 13, 2014
SOUTH SAN FRANCISCO, Calif. , Aug. 6, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today that its second quarter 2014 financial results will be released after close of market on Wednesday, August 13 , 2014.  Following the announcement, Veracyte's management will host a live
View HTML

Events

Date Event Details
Summary Toggle May 23, 2018 9:00 AM EDT
2018 UBS Global Healthcare Conference
Summary Toggle May 1, 2018 1:30 PM PDT
Veracyte First Quarter 2018 Financial Results Webcast

Presentations

Title Documents

Veracyte Corporate Presentation, May 2018